...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of immunology research. >Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
【24h】

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

机译：晚期黑色素瘤患者肿瘤浸润淋巴细胞的过继细胞治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC () or IV () melanoma. All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4. The number of TILs infused ranged from 0.23?×?109 to 22.9?×?109. Regarding safety, no serious adverse effect was reported. Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions. Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up. Notably, patients treated with high percentages of CD4?
机译：黑色素瘤的免疫疗法包括采用自体肿瘤浸润淋巴细胞（TIL）的过继细胞疗法。这项单中心回顾性研究旨在评估这种治疗晚期黑色素瘤患者的疗效和安全性。纳入了2009年至2012年之间使用相同TIL扩展方法和相同治疗白介素2（IL-2）方案接受TIL治疗的所有晚期黑色素瘤患者。在皮肤或皮下转移的无菌病变内切除之后，根据先前描述的方法产生TIL，然后将其注入也接受补充皮下IL-2方案的患者中。 9名女性和1名男性因不可切除的IIIC（）或IV（）黑色素瘤而接受治疗。除1名不可切除的III期黑色素瘤（第1线）患者外，所有患者均至少接受过2种治疗，包括4种抗CTLA-4抗体。输注的TIL数量范围为0.23？×？109至22.9？×？109。关于安全性，未报告严重不良反应。治疗反应包括完全缓解，部分缓解，2次稳定和6次进展。在这4例具有临床获益的患者中，有1名患者在9年的随访中仍然活着，另有1名在8年的随访中因其他原因死亡。值得注意的是，接受高百分比CD4治疗的患者？

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号